IKAR is a critical care company established in 2007 with a focus on developing and commercializing innovative therapies for critically ill patients. The company's flagship product, INOMAX®, is the only FDA-approved drug for treating hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants. INOMAX® is offered through a comprehensive therapy package that includes the drug product, drug-delivery system, on-site training, and 24/7 technical assistance and support. This offering is available in the USA, Puerto Rico, Canada, Australia, Mexico, and Japan.
IKAR operates in the Biotechnology and Health and Wellness industries, and its last recorded investment was a $54.95M Venture Round investment on 01 October 2009. The details of the investors involved in this round are not specified.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $54.95M | - | 01 Oct 2009 | |
| Series B | $280.00M | 4 |
|
01 Mar 2007 |
| Series A | $10.00M | 4 |
|
27 Apr 2005 |
No recent news or press coverage available for IKAR.
We care about your data, and we'd love to use cookies make your experience better.